← Back to Search
Adjuvanticity And Protective Immunity Elicited By Bordetella Pertussis Antigens Encapsulated In Poly(DL-lactide-co-glycolide) Microspheres.
R. Shahin, M. Leef, J. Eldridge, M. Hudson, R. Gilley
Published 1995 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Purified Bordetella pertussis antigens, encapsulated in biodegradable poly(DL-lactide-co-glycolide) (DL-PLG) microspheres, were evaluated for their immunogenicity and ability to elicit a protective immune response against B. pertussis respiratory infection. Microencapsulated pertussis toxoid, filamentous hemagglutinin, and pertactin all retained their immunogenicity when administered parenterally. Intranasal immunization with a low dose (1 micrograms) of encapsulated filamentous hemagglutinin, pertussis toxoid, or pertactin elicited strong specific immunoglobulin G and immunoglobulin A antibody responses in respiratory secretions that were greater in magnitude than the responses elicited by the same doses of unencapsulated antigen. Intranasal immunization with as little as 1 micrograms of encapsulated pertussis antigen prior to infection reduced the bacterial recovery by 3 log10 CFU. However, intranasal immunization with the same low doses of unencapsulated antigens did not reduce infection. Intranasal administration of a combination of 1 micrograms of each of the microencapsulated pertussis antigens was more effective in reducing bacterial infection than administration of any single microencapsulated antigen. Intranasal administration of microencapsulated B. pertussis antigens elicits high levels of specific antibody coinciding with protection against infection when these microspheres are administered to the respiratory tract. These data provide evidence of the respiratory adjuvanticity of three different DL-PLC microsphere preparations, each of which contains a unique B. pertussis antigen.
This paper references
Biodegradable microspheres: vaccine delivery system for oral immunization.
J. Eldridge (1989)
Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.
M. Tamura (1982)
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.
S. Challacombe (1992)
Aerosol infection of mice with Bordetella pertussis.
Y. Sato (1980)
Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.
J. Eldridge (1991)
Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells.
E. Tuomanen (1985)
Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide).
R. Edelman (1993)
The role of macrophages in particle translocation from lungs to lymph nodes.
A. Harmsen (1985)
Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis.
F. Menozzi (1994)
The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein.
T. Katada (1983)
Direct transdiaphragmatic traffic of peritoneal macrophages to the lung.
M. Pitt (1988)
Pertussis: The histological Lesion in the Respiratory Tract.
F. Mallory (1912)
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
N. Orr (1993)
Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.
J. Storsaeter (1990)
A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions.
C. Elson (1984)
Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model.
A. Kimura (1990)
Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response.
E. Abraham (1992)
Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine.
P. Novotny (1991)
Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology.
S. Long (1990)
Protection against vaginal SIV transmission with microencapsulated vaccine.
P. Marx (1993)
EPIDEMIOLOGY OF A SMALL PERTUSSIS OUTBREAK IN KENT COUNTY, MICHIGAN.
H. J. Lambert (1965)
Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells.
E. Leininger (1991)
The crystal structure of pertussis toxin.
P. Stein (1994)
Report of the Task Force on Pertussis and Pertussis Immunization—1988
J. Cherry (1988)
Analysis of protective and nonprotective monoclonal antibodies specific for Bordetella pertussis lipooligosaccharide.
R. Shahin (1994)
This paper is referenced by
Effect of vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles.
S. Somavarapu (2005)
Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system
H. Wu (1997)
Eighty-Kilodalton N-Terminal Moiety of Bordetella pertussis Filamentous Hemagglutinin: Adherence, Immunogenicity, and Protective Role
S. Alonso (2002)
Polyester Particles for Drug Delivery to the Skin: Local and Systemic Applications
M. Kumar (2017)
Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells
E. Ryan (1999)
Intranasal immunization against influenza virus using polymeric particles.
D. Lemoine (1999)
Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with streptococcus pneumoniae.
S. Trollé (2000)
Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine : Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th 1 and Th 2 Cells
E. Ryan (1999)
Recent advances in immunological adjuvants: the development of particulate antigen delivery systems.
D. O'hagan (1998)
Conference Science Medal Lecture: Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration *
D. O'hagan (1998)
Inhaled Vaccines for the Prevention of Tuberculosis
L. Garcia-Contreras (2013)
Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination.
P. Johansen (2000)
Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.
M. Singh (2004)
Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres.
S. Pecquet (2000)
Microparticle-based technologies for vaccines.
D. O'hagan (2006)
A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin.
A. Berstad (1997)
Protective Immunity to Bordetella pertussis Requires Both B Cells and Cd4+ T Cells for Key Functions Other than Specific Antibody Production
M. Leef (2000)
Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.
G. Lowell (1996)
Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.
G. Lowell (1996)
Recent developments in adjuvants for vaccines against infectious diseases.
D. O'hagan (2001)
Pertussis antigens that abrogate bacterial adherence and elicit immunity.
M. Brennan (1996)
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.
D. O'hagan (1997)
Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens.
E. Fattal (2002)
Microparticles as vaccine adjuvants and delivery systems
D. O'hagan (2003)
In vivo fate and immune pulmonary response after nasal administration of microspheres loaded with phosphorylcholine-thyroglobulin.
S. Trollé (1999)
A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.
A. Berstad (2000)
Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
Polymer‐grafted starch microparticles for oral and nasal immunization
M. Mcdermott (1998)
In Vivo Activation of Naive CD4+ T Cells in Nasal Mucosa-Associated Lymphoid Tissue following Intranasal Immunization with Recombinant Streptococcus gordonii
D. Medaglini (2006)
Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles.
S. Sharma (2012)
Microparticles and polymers for the mucosal delivery of vaccines.
O’Hagan (1998)See more